Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics: Schedule 13G/A reporting beneficial ownership. Caligan Partners LP and David Johnson filed an amended Schedule 13G/A reporting beneficial ownership of 1,635,023 shares of Avalo Therapeutics common stock, representing 7.2% of the class based on 22,788,452 shares outstanding as of March 18, 2026.
The filing attributes the position to Caligan and to Mr. Johnson as managing partner; the shares are reported with shared voting and shared dispositive power. The filing is signed by Mr. Johnson on behalf of both reporting persons.
Avalo Therapeutics Inc filing reports that T. Rowe Price Investment Management, Inc. holds 2,162,684 shares of common stock, equal to 9.5% of the class. The filer states it denies beneficial ownership of the securities and the filing reflects ownership and voting/dispositive powers as reported.
Avalo Therapeutics, Inc. ownership disclosure: Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 1,410,000 shares of Common Stock, representing 5.75% of the class. The percentage uses a base of 24,502,449 shares outstanding as of March 26, 2026. The disclosure is filed on Schedule 13G and lists sole voting and dispositive power over the reported shares by the reporting persons.
Avalo Therapeutics reports that Affinity Asset Advisors, LLC and Michael Cho beneficially own 1,340,840 shares of Common Stock as of March 31, 2026. This position represents approximately 5.5% of the company's Common Stock based on 24,502,449 shares outstanding as of March 26, 2026. The filing states the shares are directly held by Affinity Healthcare Fund, LP, with the Adviser exercising sole voting and dispositive power over those shares.
Avalo Therapeutics reported a net loss of $19.6 million for the quarter ended March 31, 2026, wider than $13.1 million a year earlier, as it increased investment in its pipeline. Research and development spending rose to $14.0 million, driven by manufacturing and clinical costs for its lead IL‑1β antibody abdakibart.
The company announced positive Phase 2 LOTUS data in hidradenitis suppurativa, where abdakibart met the primary HiSCR75 endpoint at both doses, with about 42.5% combined responders versus 25.6% on placebo. On March 31, 2026, Avalo held $82.0 million in cash and short-term investments, then strengthened its balance sheet with a follow-on equity and pre-funded warrant offering generating approximately $431.3 million in gross proceeds and expected net proceeds of about $405.0 million. Management now expects current cash resources and this capital raise to fund operations into 2029 while advancing abdakibart into a registrational Phase 3 program.
Avalo Therapeutics reported a larger net loss for the first quarter of 2026 while delivering positive clinical and financing milestones. Net loss was $19.6 million, compared with $13.1 million a year earlier, as research and development spending increased to $14.0 million and general and administrative expenses to $6.9 million.
The company ended March 31, 2026 with $82.0 million in cash, cash equivalents and short-term investments, and later completed an underwritten public offering of common stock and pre-funded warrants for gross proceeds of $431.3 million, or approximately $405.0 million net, extending its cash runway into 2029.
Clinically, Avalo reported positive topline Phase 2 LOTUS results for its lead asset abdakibart in moderate to severe hidradenitis suppurativa, meeting the primary endpoint at both doses with around 42% absolute improvement in HiSCR75 response rates at Week 16 versus 25.6% for placebo, and plans to advance into a registrational phase 3 program.
Avalo Therapeutics, Inc. Schedule 13G: TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu report beneficial ownership of 3,017,120 shares of Common Stock, representing 7.9% of outstanding shares based on 38,242,757 outstanding as of May 5, 2026. The filing notes an exclusion of 2,900,662 shares issuable upon conversion of Series C Preferred Stock that are not convertible within 60 days due to a 4.99% Beneficial Ownership Limitation. The reported holdings reflect shared voting and dispositive power among the reporting entities and the reporting individual.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported an option exercise and related share sale. On May 7, 2026, he exercised stock options to acquire 18,606 shares of common stock at $9.88 per share and then sold 18,606 shares in an open-market transaction at an average price of $24.1222 per share.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025, with sale prices ranging from $24.05 to $24.23. Following these transactions, he directly holds 423 shares of common stock and 168,094 stock options with a $9.88 exercise price expiring on August 13, 2034.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale related to an exercise of stock options of 18,606 shares of Common stock on 05/07/2026 for cash. The filing also lists recent 10b5-1 sales by Christopher Sullivan totaling multiple transactions in April–May 2026, including a 47,000-share sale on 05/06/2026.
Avalo Therapeutics Chief Legal Officer Paul Varki reported a mix of option exercises and share sales in Avalo Therapeutics, Inc. common stock. On May 6, 2026, he exercised stock options to acquire a total of 75,063 shares of common stock at exercise prices of $8.04 and $13.43 per share.
On the same date, he sold 75,063 shares of common stock in open-market transactions at prices ranging from $18.50 to $22.88 per share. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance as part of a trading program.